Management of patients with atherosclerotic carotid occlusion
1Department of Neurology, University of North Carolina at Chapel Hill, Box 7025, Room 2131, 170 Manning Drive, Chapel Hill, NC, 27599, USA, powersw@neurology.unc.edu.
Insights
For acute ischemic stroke from atherosclerotic carotid artery occlusion, alteplase is recommended if eligible. Otherwise, aspirin is advised, while bypass surgery and other procedures offer no proven benefit for stroke prevention.
Area of Science:
- Neurology
- Vascular Surgery
- Cardiology
Background:
- Atherosclerotic carotid artery occlusion (ACAO) is a significant cause of ischemic stroke.
- Effective management strategies for acute and recurrent stroke due to ACAO are crucial.
Purpose of the Study:
- To outline evidence-based recommendations for the acute treatment of stroke caused by ACAO.
- To provide guidance on secondary stroke prevention in patients with ACAO.
- To clarify the role of surgical and endovascular interventions for ACAO.
Main Methods:
- Review of existing clinical guidelines and evidence for ACAO management.
- Analysis of treatment outcomes for intravenous thrombolysis, antiplatelet therapy, and surgical interventions.
- Evaluation of data regarding the prognosis of asymptomatic carotid occlusion.
Main Results:
- Intravenous alteplase is recommended for eligible acute ischemic stroke patients with ACAO.
- Aspirin is indicated for non-eligible patients; heparin is not beneficial.
- Antiplatelet therapy, lifestyle modification, and risk factor intervention are recommended for secondary prevention.
- Extracranial-intracranial bypass surgery and other procedures show no proven benefit for ACAO-related stroke.
- Asymptomatic carotid occlusion generally has a benign prognosis requiring conservative management.
Conclusions:
- Treatment decisions for acute stroke due to ACAO should align with established eligibility criteria for thrombolysis.
- Medical management, including antiplatelet therapy, is the cornerstone of secondary stroke prevention in ACAO.
- Surgical and endovascular interventions are not recommended for routine treatment or prevention of stroke in ACAO.
Opinion Statement:
• Patients with acute ischemic stroke due to atherosclerotic carotid artery occlusion (ACAO) should receive intravenous tissue plasminogen activator (alteplase) if they meet eligibility criteria of the National Institute of Neurological Disorders and Stroke (NINDS) or the European Cooperative Acute Stroke Study III (ECASS III). • Patients with acute stroke due to ACAO who are not eligible for intravenous tissue plasminogen activator should receive aspirin. Heparin or heparin-like drugs do not improve outcome and should not be used. • Therapy for prevention of recurrent stroke in patients with ACAO should consist of lifestyle modifications, risk factor intervention, and antiplatelet drugs. Warfarin is not indicated. • Extracranial-intracranial bypass surgery provides no benefit over medical therapy in preventing recurrent stroke in a general population of patients with ACAO or in any subgroups selected by clinical, arteriographic, or hemodynamic criteria. • Other surgical or endovascular procedures have no proven value in treating or preventing stroke due to ACAO. • Asymptomatic carotid occlusion has a benign prognosis and requires no specific treatment other than lifestyle modification and risk factor intervention.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Coronary Artery Disease V: Interprofessional Care
Angina IV: Management
Peripheral Artery Disease III: Interprofessional Care
Aneurysm III: Interprofessional Care
